Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has earned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $8.50.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gain Therapeutics in a report on Friday, April 10th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Apollon Wealth Management LLC lifted its holdings in Gain Therapeutics by 33.7% during the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares during the last quarter. Millennium Management LLC bought a new position in Gain Therapeutics during the 4th quarter worth $45,000. Engineers Gate Manager LP bought a new position in Gain Therapeutics during the 4th quarter worth $47,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth $120,000. Finally, Marshall Wace LLP boosted its position in shares of Gain Therapeutics by 849.3% in the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after acquiring an additional 1,487,186 shares during the period. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Price Performance

NASDAQ:GANX opened at $1.82 on Thursday. Gain Therapeutics has a 12-month low of $1.41 and a 12-month high of $4.34. The firm has a market capitalization of $77.63 million, a price-to-earnings ratio of -2.98 and a beta of 0.15. The stock’s 50 day moving average price is $2.11 and its two-hundred day moving average price is $2.39. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.02.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same period last year, the business earned ($0.16) EPS. On average, analysts anticipate that Gain Therapeutics will post -0.54 earnings per share for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.